Program Description
IgA nephropathy (IgAN) is a progressive, rare autoimmune kidney disease. Despite traditional management, roughly 30% to 50% of affected individuals progress to end-stage kidney disease (ESKD) within 20 to 30 years of diagnosis. This webinar establishes a comprehensive clinical foundation, reviewing IgAN epidemiology, burden of illness, and its complex multihit pathogenesis while highlighting the pivotal roles of proteinuria and the BAFF/APRIL and endothelin signaling pathways in disease progression. The recent publication of 2025 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline updates requires that pharmacists be familiar with evidence-based paradigm shifts toward early, simultaneous intervention aimed at achieving near-physiologic rates of estimated glomerular filtration rate (eGFR) loss and targeting strict, lower protein thresholds. Beyond maximizing traditional renin-angiotensin system (RAS) blockade, this program equips pharmacists with the clinical trial data and unique mechanisms of newly FDA-approved and emerging targeted therapies. Primary evidence from landmark trials for approved and emerging agents will be discussed. The webinar will also highlight best practices to implement care coordination strategies, patient-centered counseling to address quality-of-life impacts, routine eGFR/proteinuria monitoring adherence, and solutions to overcome access barriers for these novel treatments.
Target audience: Health-system and specialty pharmacists
Type of activity: Application
Release date: October 30, 2026
Expiration date: October 30, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the epidemiology, key disease mechanisms, and common risk factors associated with IgA nephropathy (IgAN), along with typical clinical manifestations and effects on patient quality of life
- Examine current KDIGO recommendations for IgAN and their application in tailoring patient-specific treatment strategies
- Investigate the evolving treatment landscape for IgAN, including novel therapies, their mechanisms of action, and the clinical evidence supporting their use
- Identify the role of the pharmacist in care coordination and practical approaches to support early recognition, appropriate intervention, and optimization of long-term kidney outcomes
Jesse Rungkitwattanakul, PharmD, BCPS, FNKF, FASN
Associate Professor
Nephrology Pharmacist
Howard University College of Pharmacy
Howard University Hospital
Washington, DC
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This Application-based activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-337-H01-P. The activity is available for CE credit through October 30, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
The following contributors have no relevant financial relationships with ineligible companies to disclose:
Faculty
Jesse Rungkitwattanakul, PharmD, BCPS, FNKF, FASN
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Jason Christidhis, PharmD; Sarah Viruet; and Brianna Winters
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
